Trial · NCT01469156
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups. | 2 years | Adverse events | NUMBER | |
| SECONDARY | Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months | 12 months | Randomized in a 3:1 ratio - number in participant flow is 20 | letters | MEAN |
| SECONDARY | Change in Mean Central Foveal Thickness From Baseline | 12 Months | Randomized in a 3:1 ratio | um | MEAN |
| SECONDARY | Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months | 12 Months | Randomized in a 3:1 ratio | mm^2 | MEAN |
| SECONDARY | Number of Participants at Month 3 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters | 3 Months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants at Month 6 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters | 6 months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants at Month 9 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters | 9 Months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants at Month 12 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters | 12 Months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mean Change Best Corrected Visual Acuity at 4 Meters at Baseline, Month 3, Month 6, Month 9, and Month 12 | 12 months | Randomized in a 3:1 ratio - number in participant flow is 20 | letters | MEAN |
| SECONDARY | Number of Participants at Month 3 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters | 3 months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants at Month 6 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters | 6 months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants at Month 9 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters | 9 months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants at Month 12 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters | 12 months | Randomized in a 3:1 ratio - number in participant flow is 20 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01469156/outcomes